中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(4): 843-850

Value of inflammatory biomarkers in predicting the prognosis of early small hepatocellular carcinoma after radiofrequency ablation

DOI: 10.3969/j.issn.1001-5256.2022.04.020
  • 1.

    Graduate School of Tianjin Medical University, Tianjin 300070, China

  • 2.

    Tianjin Institute of Hepatology, Department of Traditional and Western Medical Hepatology, Tianjin Second People's Hospital, Tianjin 300192, China

Research funding:

Chinese Foundation for Hepatitis Prevention and Control (2021038)

More Information
  • Corresponding author: LI Ping, tjlplxg@163.com (ORCID: 0000-0001-9930-6429)
  • Received Date: 2021-08-10
  • Accepted Date: 2021-09-24
  • Published Date: 2022-04-20
    Abstract
  •   Objective  To investigate the value of neutrophil-to-lymphocyte ratio (NLR), red blood cell distribution width-to-lymphocyte ratio (RLR), and lymphocyte-to-monocyte ratio (LMR) in predicting the prognosis of early small hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA).  Methods  A retrospective analysis was performed for 132 patients newly diagnosed with early HCC who underwent RFA in Tianjin Second People's Hospital from September 2011 to December 2020. Preoperative data were collected and the patients were followed up to observe recurrence and overall survival (OS). The X-tile tool was used to determine the optimal cut-off values of NLR, RLR, and LMR based on 5-year survival rate and recurrence-free survival (RFS) rate, and then the patients were divided into N-R-L 0 group with 92 patients, N-R-L 1 group with 29 patients, and N-R-L 2 group with 11 patients. The chi-square test was used for comparison of categorical data between the three groups. The Kaplan-Meier method was used to plot the survival curve, and the log-rank test was used to compare RFS and OS rates between groups. The factors with statistical significance in the log-rank test were included in the multivariate Cox regression analysis to determine the risk factors for RFS and OS rates.  Results  There were significant differences in Child-Pugh class and albumin between the N-R-L 0, N-R-L 1, and N-R-L 2 groups (χ22=10.992 and 5.699, both P < 0.05). The 1-, 3-, and 5-year OS rates of the three groups were 100%/96.3%/90.7%, 96.6%/60.4%/41.3%, and 81.8%/46.8%/15.6%, respectively (χ2=38.46, P < 0.000 1), and the 1-, 3-, and 5-year RFS rates of the three groups were 76.9%/52.5%/33.3%, 42.9%/13.1%/0, and 11.1%/0/0, respectively (χ2=35.345, P < 0.000 1). The multivariate Cox regression analysis showed that tumor diameter ≥ 2 cm (hazard ratio[HR]=2.10, 95% confidence interval[CI]: 1.28-3.43, P=0.003; HR=3.67, 95% CI: 1.58-8.52, P=0.002), N-R-L score of 1 point (HR=3.14, 95% CI: 1.81-5.46, P < 0.000 1; HR=8.27, 95% CI: 3.15-21.71, P < 0.000 1), and N-R-L score of 2 points (HR=2.61, 95% CI: 1.06-6.42, P=0.037; HR=14.59, 95% CI: 3.96-53.78, P < 0.000 1) were independent predictive factors for RFS and OS.  Conclusion  N-R-L, a systemic inflammatory response marker composed of NLR, RLR, and LMR, is an independent risk factor for recurrence and survival of early small HCC after RFA, and it can be used as a useful noninvasive biomarker in combination with tumor features to predict the recurrence and survival of early HCC after RFA.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604. DOI: 10.1038/s41575-019-0186-y.
    [2]
    Bureau of Medical Administration National Health Commission of the People' s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [3]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [4]
    KIM GA, SHIM JH, KIM MJ, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas[J]. Br J Surg, 2016, 103(1): 126-135. DOI: 10.1002/bjs.9960.
    [5]
    TANG JQ, HE P, SU S, et al. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocelluar carcinoma: A Meta-analysis[J]. J Clin Hepatol, 2020, 36(2): 358-362. DOI: 10.3969/j.issn.1001-5256.2020.02.025.

    汤金全, 何攀, 苏松, 等. 射频消融术和微创切除术治疗小肝细胞癌短期及长期效果比较的Meta分析[J]. 临床肝胆病杂志, 2020, 36(2): 358-362. DOI: 10.3969/j.issn.1001-5256.2020.02.025.
    [6]
    LI R, CHEN HP, WANG F, et al. Application of contrast-enhanced ultrasound combined with percutaneous radiofrequency ablation in the treatment of rupture and bleeding of liver cancer[J]. Chin J Gerontol, 2020, 40(17): 3653-3656. DOI: 10.3969/j.issn.1005-9202.2020.17.021.

    李锐, 陈卉品, 王菲, 等. 超声造影联合经皮射频消融在肝癌破裂出血治疗中的应用[J]. 中国老年学杂志, 2020, 40(17): 3653-3656. DOI: 10.3969/j.issn.1005-9202.2020.17.021.
    [7]
    DIAKOS CI, CHARLES KA, MCMILLAN DC, et al. Cancer-related inflammation and treatment effectiveness[J]. Lancet Oncol, 2014, 15(11): e493-e503. DOI: 10.1016/S1470-2045(14)70263-3.
    [8]
    WU ML, YANG SZ, FENG XB, et al. Prognostic value of preoperative inflammatory indicators for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 213-219. DOI: 10.3760/cma.j.cn115610-20210125-00041.

    吴美龙, 杨世忠, 冯晓彬, 等. 肝细胞癌术前炎症指标的预后价值[J]. 中华消化外科杂志, 2021, 20(2): 213-219. DOI: 10.3760/cma.j.cn115610-20210125-00041.
    [9]
    HUANG J, ZHAO Y, LIAO L, et al. Evaluation of red cell distribution width to lymphocyte ratio as potential biomarker for detection of colorectal cancer[J]. Biomed Res Int, 2019, 2019: 9852782. DOI: 10.1155/2019/9852782.
    [10]
    WU J, ZHANG X, LIU H, et al. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection[J]. Clin Biochem, 2019, 63: 24-31. DOI: 10.1016/j.clinbiochem.2018.11.012.
    [11]
    CRUZ JC, WATCHMAKER JM, ALBIN MM, et al. Neutrophil/Lymphocyte ratio predicts increased risk of immediate progressive disease following chemoembolization of hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2019, 30(12): 1887-1892. DOI: 10.1016/j.jvir.2019.08.001.
    [12]
    CAMP RL, DOLLED-FILHART M, RIMM DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization[J]. Clin Cancer Res, 2004, 10(21): 7252-7259. DOI: 10.1158/1078-0432.CCR-04-0713.
    [13]
    DOYLE A, GORGEN A, MUADDI H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3cm in potentially transplantable patients[J]. J Hepatol, 2019, 70(5): 866-873. DOI: 10.1016/j.jhep.2018.12.027.
    [14]
    CHO JY, CHOI MS, LEE GS, et al. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma[J]. Clin Mol Hepatol, 2016, 22(4): 477-486. DOI: 10.3350/cmh.2016.0048.
    [15]
    KIM YS, LIM HK, RHIM H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factors[J]. J Hepatol, 2013, 58(1): 89-97. DOI: 10.1016/j.jhep.2012.09.020.
    [16]
    LEE HY, RHIM H, LEE MW, et al. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: Analysis of risk factors[J]. Eur Radiol, 2013, 23(1): 190-197. DOI: 10.1007/s00330-012-2561-8.
    [17]
    GRETEN FR, GRIVENNIKOV SI. Inflammation and cancer: Triggers, mechanisms, and consequences[J]. Immunity, 2019, 51(1): 27-41. DOI: 10.1016/j.immuni.2019.06.025.
    [18]
    GRIVENNIKOV SI, GRETEN FR, KARIN M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140(6): 883-899. DOI: 10.1016/j.cell.2010.01.025.
    [19]
    QUAIL DF, OLSON OC, BHARDWAJ P, et al. Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF[J]. Nat Cell Biol, 2017, 19(8): 974-987. DOI: 10.1038/ncb3578.
    [20]
    NAJAFI M, FARHOOD B, MORTEZAEE K. Contribution of regulatory T cells to cancer: A review[J]. J Cell Physiol, 2019, 234(6): 7983-7993. DOI: 10.1002/jcp.27553.
    [21]
    GOODEN MJ, de BOCK GH, LEFFERS N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis[J]. Br J Cancer, 2011, 105(1): 93-103. DOI: 10.1038/bjc.2011.189.
    [22]
    RASHID F, WARAICH N, BHATTI I, et al. A pre-operative elevated neutrophil: Lymphocyte ratio does not predict survival from oesophageal cancer resection[J]. World J Surg Oncol, 2010, 8: 1. DOI: 10.1186/1477-7819-8-1.
    [23]
    CHEN Y, YANG Y, ZHANG XY, et al. Nomogram based on neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio to predict recurrence in patients with hepatocellular carcinoma after radiofrequency ablation[J]. Cardiovasc Intervent Radiol, 2021, 44(10): 1551-1560. DOI: 10.1007/s00270-021-02872-8.
    [24]
    WANG C, ZHAO K, HU S, et al. A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: Based on SUVmean and NLR[J]. BMC Cancer, 2020, 20(1): 544. DOI: 10.1186/s12885-020-07040-8.
    [25]
    POLLARD JW. Tumour-educated macrophages promote tumour progression and metastasis[J]. Nat Rev Cancer, 2004, 4(1): 71-78. DOI: 10.1038/nrc1256.
    [26]
    EVANI SJ, PRABHU RG, GNANARUBAN V, et al. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow[J]. FASEB J, 2013, 27(8): 3017-3029. DOI: 10.1096/fj.12-224824.
    [27]
    GOYAL H, HU ZD. Prognostic value of red blood cell distribution width in hepatocellular carcinoma[J]. Ann Transl Med, 2017, 5(13): 271. DOI: 10.21037/atm.2017.06.30.
    [28]
    ZHANG X, WANG D, CHEN Z, et al. Red cell distribution width-to-lymphocyte ratio: A novel predictor for HBV-related liver cirrhosis[J]. Medicine (Baltimore), 2020, 99(23): e20638. DOI: 10.1097/MD.0000000000020600.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (483) PDF downloads(47) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return